Lenacapavir PrEP Shows High Efficacy Over One Year

A year-long extension of the PURPOSE 1 and PURPOSE 2 clinical trials has demonstrated the sustained effectiveness of twice-yearly injectable lenacapavir (brand name Yeztugo) for pre-exposure prophylaxis (PrEP) in preventing HIV infections. During this extended observational period, only one participant out of the thousands enrolled developed a new HIV infection, underscoring the robust protective capabilities of the long-acting antiretroviral therapy. The original PURPOSE trials, which enrolled approximately 5,300 participants across multiple countries, had previously established lenacapavir's non-inferiority to daily oral emtricitabine/tenofovir disoproxil fumarate (Truvada) for PrEP in cisgender women and transgender men who have sex with men. The extension phase specifically focused on assessing the real-world durability and safety of the injectable formulation when administered every six months.

Lenacapavir, developed by Gilead Sciences, is a first-in-class HIV-1 capsid inhibitor. Its mechanism of action involves disrupting multiple stages of the HIV replication cycle, including nuclear import, assembly, and release of new virions. This multi-pronged attack makes it a potent tool against the virus. The injectable formulation allows for less frequent dosing compared to daily oral pills, a significant advantage for adherence, which is a critical factor in the success of PrEP. Poor adherence to daily PrEP regimens has been a persistent challenge in HIV prevention efforts, leading to breakthrough infections. The success of lenacapavir's long-acting formulation addresses this barrier directly, offering a more convenient and potentially more effective option for individuals at high risk of acquiring HIV.

The PURPOSE 1 trial was conducted in South Africa and Uganda, focusing on cisgender women, while the PURPOSE 2 trial took place in the United States, Brazil, and Peru, enrolling cisgender men and transgender women who have sex with men. The combined data from these trials, including the year-long extension, provide a comprehensive picture of lenacapavir's efficacy and safety across diverse populations and geographic settings. The single breakthrough infection observed in the extension phase is being meticulously investigated to understand the specific circumstances, including adherence to the injection schedule and potential resistance mutations, though initial analyses suggest the drug's overall effectiveness remains exceptionally high. The U.S. Food and Drug Administration (FDA) approved lenacapavir (Yeztugo) for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in individuals with multi-drug resistance in December 2022, and its potential for PrEP has been a key area of ongoing research and development.

This sustained high level of efficacy over a year in a large cohort suggests that lenacapavir's injectable formulation could significantly reshape HIV prevention strategies. By simplifying the dosing schedule to twice a year, it has the potential to improve uptake and adherence among populations that may struggle with daily pill regimens. The ongoing analysis of the extension data will provide further insights into the long-term safety profile and the real-world impact of this innovative PrEP option. The development and successful trial results of lenacapavir represent a major advancement in the global effort to end the HIV epidemic, offering a promising new tool for both prevention and treatment.